Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bocidelpar in Primary Mitochondrial Myopathy
NCT04641962Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bocidelpar in primary mitochondrial myopathy (PMM) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Change From Baseline in Distanced Walked During a 6 Minute Walk Test at 24 weeks, Number of Participants With Treatment Emergent Adverse Events at 52 weeks and 1 more. Started May 2021; status: terminated.
02
Drugs
bocidelpar
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT04641962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641962.